Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

J. Mayer, Robert; Van Cutsem, Eric; Falcone, Alfredo; Yoshino, Takayuki; García‐Carbonero, Rocio; Mizunuma, Nobuyuki; Yamazaki, Kentaro; Shimada, Yasuhiro; Tabernero, Josep; Komatsu, Yoshito; Sobrero, Alberto; Boucher, Éveline; Peeters, Marc; Tran, Ben; Lenz, Heinz‐Josef; Zaniboni, Alberto; S. Höchster, Howard; M. Cleary, James; Prenen, Hans; Benedetti, Fabio; Mizuguchi, Hirokazu; Makris, Lukas; Ito, Masanobu; Ohtsu, Atsushi

doi:10.1056/nejmoa1414325

Public

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Published in New England Journal of Medicine • May 13, 2015

Authors:

Robert J. Mayer

Eric Van Cutsem

Alfredo Falcone

Abstract

BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-...

Subject

Medicine

Hazard ratio

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!